BIOCQ - BIOCEPT INC

0.0001
0   0%

Share volume: 1
Last Updated: 04-16-2025
Healthcare/Services – Health: -0.02%

PREVIOUS CLOSE
CHG
CHG%
$0.00
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
25%
Profitability 18%
Dept financing 0%
Liquidity 0%
Performance 45%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.00
P/E Ratio 
N/A
DAY RANGE
$0.00 - $0.00
EPS 
N/A
52 WEEK RANGE
$0.00 - $0.05
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$14
AVERAGE 30 VOLUME 
$784
Company detail
CEO: Samuel D. Riccitelli
Region: US
Website: biocept.com
Employees: 190
IPO year: 2023
Issue type:
Market: OTCM
Industry: Healthcare/Services – Health
Sector: Services

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays. Assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC) and gastric cancer.

Recent news
loading